



## STEP THERAPY POLICY

- POLICY:** Diuretics – Loop Products Step Therapy Policy
- bumetanide tablets (generic only)
  - Edecrin® (ethacrynic acid tablets – Bausch/Patheon, generic)
  - Furoscix® (furosemide subcutaneous injection by on-body infusor – scPharmaceuticals)
  - Lasix® (furosemide tablets – Validus, generic)
  - Soanz® (torsemide tablets – Sarfez)
  - torsemide tablets (generic only)

**REVIEW DATE:** 06/14/2023

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

### **CIGNA NATIONAL FORMULARY COVERAGE:**

#### **OVERVIEW**

The medications included in this policy are loop diuretics. For most products, the indications for use are very similar and are noted below.

Bumetanide tablets (generic) are indicated for:<sup>1</sup>

- Treatment of **edema** associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Ethacrynic acid tablets are indicated for:<sup>2</sup>

- Treatment of **edema** associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.

Furosemide tablets are indicated for:<sup>3</sup>

- Treatment of **edema** associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
- Treatment of **hypertension**, alone or in combination with other antihypertensive agents, in adults.

Furoscix is indicated for:<sup>4</sup>

- Treatment of **congestion due to fluid overload in adults with New York Heart Association Class II and III chronic heart failure**. Limitations of Use: Furoscix is not indicated for use in emergency situations or in patients with acute pulmonary edema. Of note, the single-use, on-body infusor with prefilled cartridge is pre-programmed to deliver 30 mg of Furoscix subcutaneously (SC) over the first hour, followed by 12.5 mg per hour for the subsequent 4 hours (80 mg SC over a total of 5 hours). Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.

Soanz is indicated for:<sup>5</sup>

- Treatment of **edema** associated with heart failure or renal disease in adults.
- Treatment of **hypertension**, alone or in combination with other antihypertensive agents, in adults.

Torsemide tablets (generic) are indicated for:<sup>6</sup>

- Treatment of **edema** associated with heart failure, renal disease or hepatic disease.
- Treatment of **hypertension**, to lower blood pressure.

## **POLICY STATEMENT**

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

**Diuretics – Loop Products product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.**

**Step 1:** bumetanide tablets, ethacrynic acid tablets, furosemide tablets, torsemide tablets

**Step 2:** Edecrin tablets, Lasix tablets, Soanz tablets, Furoscix

## **CRITERIA**

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.

## REFERENCES

1. Bumex® tablets [prescribing information]. Parsippany, NJ: Validus; August 2018.
2. Edecrin® tablets and Sodium Edecrin® intravenous solution [prescribing information]. Bridgewater, NJ and Greenville, NC; Bausch and Patheon; August 2020.
3. Lasix® tablets [prescribing information]. Parsippany, NJ: Validus; August 2018.
4. Furoscix® subcutaneous injection by on-body infusor [prescribing information]. Burlington, MA: scPharmaceuticals; October 2022.
5. Soanz® tablets [prescribing information]. Vienna, VA: Sarfex; June 2021.
6. Demadex® tablets [prescribing information]. Somerset, NJ: Meda; February 2017.

## HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	06/08/2022
Selected Revision	<b>Furoscix:</b> Furoscix was added as a Step 2 product.	01/11/2023
Annual Revision	No criteria changes.	06/14/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna